Telephone Delivery of BRCA Genetic Counseling

Video

This video explores a study that found telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.

A recent study found that use of telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.

In this video, lead study author Anita Y. Kinney, PhD, RN, of the University of New Mexico in Albuquerque, discusses the results of the study. Click here to read more.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
Related Content
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer

April 11th 2024
Article

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024
Article

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Population Testing to Prevent Gynecologic Cancers

Population Testing to Prevent Gynecologic Cancers

September 12th 2018
Podcast

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer

March 24th 2024
Article

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.

FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

March 22nd 2024
Article

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.